|
|
|
| Clinical analysis of 273 adverse drug reaction reports of antineoplastics in our hospital |
| WU Haiwei BAI Yu LIU Hong ZHANG Yanhua▲ |
| Key Laboratory of Malignant Tumor Pathogenesis and Translational Research of Ministry of Education, Department of Pharmacy, Beijing Cancer Hospital of Peking University Beijing Institute for Cancer Research, Beijing 100142, China |
|
|
|
Abstract Objective To analyze the characteristics and general rules of adverse drug reaction (ADR) in Beijing Cancer Hospital of Peking University ("our hospital" for short) in order to provide reference for further developing clinical pharmaceutist guiding rational drug use, and reduce the incidence of ADR. Methods The ADRs reports in our hospital from September 2015 to September 2016 were downloaded from the national ADR monitoring system, and the ADRs of antineoplastic drugs were screened, and the data was taken statistics and analysis by excel software. Results Among 273 cases of ADRs caused by antineoplastic drugs reported from September 2015 to September 2016, there were 19 cases of ADRs caused by auxiliary antineoplastic drugs. The male to female ratio of ADRs was 0.9∶1, the age group was mainly concentrated in 50-＜60 years old, total 92 cases (33.70%). The main route of administration causing ADRs was intravenous dripping (255 cases, 93.41%). The organs or systems involved by ADRs were constitutional reaction (27.97%), skin reaction (16.52%) and cardiovascular system reaction (13.22%). The main clinical symptoms were allergic reactions (51 cases, 11.23%), shortness of breath (33 cases, 7.27%), fever (28 cases, 6.17%), chest distress (27cases, 5.59%) and skin rush (26 cases, 5.73%). The highest incidence rate of ADR drugs were Oxaliplatin (71 cases, 20.70%) and Paclitaxel (57 cases, 16.62%). Conclusion Clinical pharmacist should take initiative to monitor ADR of antineoplastics drugs. Combined with detection of pharmacogenomics, clinical pharmacist should formulate individualized treatment plan, so as to promote rational drug use, prevent and reduce the incidence of ADRs.
|
|
|
|
|
|
[1] 曾倩，崔芳芳，宇传华，等.中国癌症发病、死亡现状与趋势分析[J].中国卫生统计，2016，33（2）：321-323.
[2] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[3] 刘琳琳，孙言才，姜玲，等.661例抗肿瘤药不良反应报告回顾性分析[J].药物流行病学杂志，2011，20（5）：229-232.
[4] 李蓉，董志，路晓钦，等.重庆市818例抗肿瘤药不良反应报告分析[J].中国药房，2013，24（34）：3225-3227.
[5] 权修权，朴惠顺，康琳，等.抗肿瘤靶向药物研究现状[J].中国药理学通报，2015，31（5）：610-614.
[6] Hou Y，Li X，Wu G，et al. National ADR Monitoring System in China [J]. Drug Saf，2016，39（11）：1043-1051.
[7] 曹媛，夏延哲，闫佳佳.132例抗肿瘤药物不良反应分析[J].今日药学，2016，26（3）：190-193.
[8] 李泽辉，王晓丹，李宝笙.95例抗肿瘤药物的不良反应报告分析[J].药物警戒，2008，5（2）：104-107.
[9] 钱钧强，孙蓓.抗肿瘤药物多药耐药性的研究进展[J].中国肿瘤临床，2011，38（11）：684-687.
[10] 黎小妍，张二红，刘玉兴，等.肿瘤多药耐药机制及其逆转方案的研究[J].中国处方药，2012，10（4）：24-30.
[11] 郑瑜，郑滢，林静容，等.我院抗肿瘤药物不良反应报告分析[J].中国医药导报，2010，7（34）：110-113.
[12] 刘红，张艳华.我院281例抗肿瘤药致不良反应报告分析[J].中国药房，2011，22（38）：3607-3610.
[13] 甘戈，孙骏.1956例抗肿瘤药物不良反应/事件报告分析[J].中国药物警戒，2009，6（4）：231-235.
[14] Hesketh PJ. Chemotherapy-induced nausea and vomiting [J]. N Engl J Med，2008，358（23）：2482-2494.
[15] Janelsins MC，Tejani MA，Kamen C，et al. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients [J]. Expert Opin Pharmacother，2013，14（6）：757-766.
[16] Navari RM，Aapro M. Antiemetic prophylaxis for chemo-therapy-induced nausea and vomiting [J]. N Engl J Med，2016，374（14）：1356-1367.
[17] 周林平，李璇.紫杉醇脂质体对非小细胞肺癌患者的抗肿瘤作用研究[J].中国医学创新，2016，13（33）：123-126.
[18] 罗新.药品不良反应成因分析及预防措施分析[J].中外医学研究，2016，14（4）：152-153.
[19] 李德爱，王大志，张书瑜，等.抗肿瘤药物与化疗患者发生骨髓抑制情况的药物流行病学研究[J].中国药学杂志，2010，45（24）：1968-1970.
[20] 刘晅.化疗对恶性肿瘤患者的疗效及所致中性粒细胞减少分析[J].中国实用医药，2012，7（19）：67-68.
[21] Crawford J，Dale DC，Lyman GH. Chemotherapy-induced neutropenia：risks，consequences，and new directions for its management [J]. Cancer，2004，100（2）：228-237.
[22] 朱青，徐丽华.抗肿瘤药致骨髓抑制的相关因素分析[J].药学与临床研究，2015，23（1）：68-70. |
|
|
|
